Octozi
Reviewed active Updated Jul 7, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
Founders
About
Octozi is a New York-based AI company that automates clinical trial data cleaning, review, reconciliation, and reporting for pharmaceutical sponsors using an agentic, human-in-the-loop platform 123. Founded in 2023, the company is led by Co-Founder and CEO Amit Patel 13. In a controlled study, Octozi’s AI assistance increased data cleaning throughput approximately six-fold and reduced reviewer error rates from 54.7% to 8.5%, while lowering false-positive queries approximately fifteen-fold; an accompanying economic analysis estimated savings of more than $5 million per representative Phase III oncology trial 12. Prior to the Seed round, Octozi received strategic investment from the venture arm of Swiss pharmaceutical company Debiopharm 13.
Disclaimer: This is a lean profile built from initial round coverage and may be expanded as more information becomes available.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-07-07 | Seed | $3M | Surface Ventures | Remarkable Ventures 123 |
| ~2024 (prior to Seed) | Strategic | Undisclosed | Debiopharm (venture arm) | 13 |
What Investors Say
“Octozi brings value to pharmaceutical companies in multiple ways. It improves the quality of data submitted to regulatory bodies; it helps clinical development and data teams with their day to day work, allowing them to be less of a bottleneck in all the trials they may be managing; and it speeds up the time on specific tasks.” — Gyan Kapur, Managing Partner, Surface Ventures 1
What Founders Say
“Most tools in this space put trial data on a dashboard and leave the analysis to clinical teams. Octozi was built to perform that work alongside the people who own the data, with the human in control and the model handling tasks that previously took weeks of manual effort.” — Amit Patel, Co-Founder & CEO, Octozi 1
“Clinical development is one of the most expensive and time-consuming processes in any industry, and the data operations layer underneath it has barely changed in decades. We think purpose-built AI, designed around how clinical teams actually work, can compress timelines, reduce risk, and bring down cost across the entire development cycle.” — Amit Patel, Co-Founder & CEO, Octozi 1
Sources
-
Swace News (via GlobeNewswire), “Octozi Raises $3M in Seed Funding to bring Agentic AI to Clinical Development,” July 7, 2026. Accessed July 2026. https://www.swacenews.com/2026/07/07/octozi-raises-3m-in-seed-funding-to-bring-agentic-ai-to-clinical-development/↩↩↩↩↩↩↩↩↩
-
AlleyWatch, “The AlleyWatch Startup Daily Funding Report: 7/7/2026,” July 7, 2026. Accessed July 2026. https://www.alleywatch.com/2026/07/the-alleywatch-startup-daily-funding-report-7-7-2026/↩↩↩
-
The Manila Times (via GlobeNewswire), “Octozi Raises $3M in Seed Funding to bring Agentic AI to Clinical Development,” July 7, 2026. Accessed July 2026. https://www.manilatimes.net/2026/07/07/tmt-newswire/globenewswire/octozi-raises-3m-in-seed-funding-to-bring-agentic-ai-to-clinical-development/237997↩↩↩↩↩